NCT04590274 is a Phase 1 clinical trial of Hydroxychloroquine in Covid19, sponsored by International Brain Research Foundation.

Who is sponsoring NCT04590274?

NCT04590274 is sponsored by International Brain Research Foundation.

What drugs are being tested in NCT04590274?

Interventions in NCT04590274: Hydroxychloroquine, Vitamins and Minerals, Azithromycin.

What condition does NCT04590274 study?

NCT04590274 studies Covid19, SARS (Severe Acute Respiratory Syndrome).

Is NCT04590274 still recruiting?

NCT04590274 is currently withdrawn. Last updated 5 December 2021.

Last reviewed 2021-12-05 · How we verify

NCT04590274

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Withdrawn Phase 1 Last updated 5 December 2021

What this trial tests

Phase 1 trial testing Hydroxychloroquine in Covid19. Withdrawn.

Timeline

1 November 2020

Primary endpoint
1 December 2021

1 December 2021

Quick facts

Lead sponsor	International Brain Research Foundation
Phase	Phase 1
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Start date	1 November 2020
Primary completion	1 December 2021
Estimated completion	1 December 2021

Drugs / interventions tested

Hydroxychloroquine (HYDROXYCHLOROQUINE) — full drug profile →
Vitamins and Minerals
Azithromycin (azithromycin) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →
SARS (Severe Acute Respiratory Syndrome) — all drugs for SARS (Severe Acute Respiratory Syndrome) →

Sponsor

International Brain Research Foundation

Who can join

Eligibility, any sex, with Covid19 or SARS (Severe Acute Respiratory Syndrome). Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of individuals who develop COVID-19 symptoms
Time frame: 6 months from study start
The investigators will compare what percentage of participants in this study go on to develop COVID-19 symptoms, as compared to individuals not on the medicational regimen in this study.

Sponsor's own description

Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family. The coronaviruses are largely responsible for the common cold, the 2002 SARS outbreak in Guangdong, China, the 2012 MERS outbreak in Saudi Arabia, and the present COVID-19 outbreak that originated in Wuhan, China. Much has been reported by way of systemic injury caused by COVID-19 affecting the cardiovascular, hepatic, nervous systems. These conditions are likely the result of the virus overwhelming the immune system. For these reasons, the investigators wish to conduct this study using existing medications off-label, and over-the-counter supplements to support the immune response, prevent lasting injury, and hasten the recovery from COVID-19.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects.
Lisco G, De Tullio A, Jirillo E, Giagulli VA, et al · · 2021 · cited 62× · PMID 33765288 · DOI 10.1007/s40618-021-01554-z
The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature.
Imran M, Thabet HK, Alaqel SI, Alzahrani AR, et al · · 2022 · cited 45× · PMID 35624740 · DOI 10.3390/antiox11050876
TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2.
Kaushik D, Bhandari R, Kuhad A. · · 2021 · cited 45× · PMID 33857397 · DOI 10.1080/14728222.2021.1918103
Potential molecular mechanisms of zinc- and copper-mediated antiviral activity on COVID-19.
Rani I, Goyal A, Bhatnagar M, Manhas S, et al · · 2021 · cited 43× · PMID 34284268 · DOI 10.1016/j.nutres.2021.05.008
Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention.
Gligorijevic N, Radomirovic M, Nedic O, Stojadinovic M, et al · · 2021 · cited 14× · PMID 34830267 · DOI 10.3390/ijms222212385
Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents.
Imran M, Fatima W, Alzahrani AK, Suhail N, et al · · 2022 · cited 13× · PMID 35334884 · DOI 10.3390/nu14061227
A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions.
Pawar A, Russo M, Rani I, Rani I, et al · · 2022 · cited 12× · PMID 35393674 · DOI 10.1002/ptr.7461
Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment.
Zou H, Yang Y, Dai H, Xiong Y, et al · · 2021 · cited 12× · PMID 34880750 · DOI 10.3389/fphar.2021.732403

Verify or expand the search:

Other trials of Hydroxychloroquine

Trials testing the same drug.

NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06971744 — Autophagy Maintenance (AUTOMAIN) · Phase 2 · recruiting
NCT05841758 — Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis · Phase 4 · recruiting

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04590274 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International Brain Research Foundation
Last refreshed: 5 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04590274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing